Tumour-Infiltrating Clonal Haematopoiesis Increases the Risk of Recurrence or Death Among Patients with NSCLC and the Risk of Death From Any Cause Among Patients with Solid Tumours By Ogkologos - May 7, 2025 619 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the analysis of TRACERx and MSK-IMPACT studies Source RELATED ARTICLESMORE FROM AUTHOR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe MOST POPULAR AI-Based Score as a Selection Tool for Supplemental MRI After Negative... July 29, 2024 COVID-19 Vaccines: Considerations for Special Populations February 4, 2021 Clinical Trials in Molecular Testing for Early-Stage Lung Cancer: IMpower010, ADAURA,... June 15, 2022 FDA Grants Regular Approval to Pembrolizumab and Lenvatinib for Advanced Endometrial... July 23, 2021 Load more HOT NEWS Few People with Cancer Undergo Testing for Inherited Gene Mutations Diving into our role in 50 top cancer drugs Pembrolizumab Approved for Some Patients with Advanced Esophageal Cancer Longitudinal Molecular Profiling of CTCs Captures New Insights in mRCC
